DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime? by van de Pavert, S. H. P. et al.
RESEARCH PAPER
DIR-visible grey matter lesions and atrophy
in multiple sclerosis: partners in crime?
Steven H P van de Pavert,1 Nils Muhlert,1,2 Varun Sethi,1 Claudia A M Wheeler-Kingshott,1
Gerard R Ridgway,3,4 Jeroen J G Geurts,5 Maria Ron,1 Tarek A Yousry,6
Alan J Thompson,1,7 David H Miller,1,7 Declan T Chard,1,7 Olga Ciccarelli1,7
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
jnnp-2014-310142).
For numbered afﬁliations see
end of article.
Correspondence to
Steven Harry Pieter van de
Pavert, Institute of Neurology,
University College London,
WC1N 3BG, UK;
s.pavert@ucl.ac.uk
Received 22 December 2014
Revised 30 March 2015
Accepted 10 April 2015
To cite: van de Pavert SHP,
Muhlert N, Sethi V, et al.
J Neurol Neurosurg Psychiatry
Published Online First: [please
include Day Month Year]
doi:10.1136/jnnp-2014-
310142
ABSTRACT
Background The extent and clinical relevance of grey
matter (GM) pathology in multiple sclerosis (MS) are
increasingly recognised. GM pathology may present as
focal lesions, which can be visualised using double
inversion recovery (DIR) MRI, or as diffuse pathology,
which can manifest as atrophy. It is, however, unclear
whether the diffuse atrophy centres on focal lesions. This
study aimed to determine if GM lesions and GM atrophy
colocalise, and to assess their independent relationship
with motor and cognitive deﬁcits in MS.
Methods Eighty people with MS and 30 healthy
controls underwent brain volumetric T1-weighted and
DIR MRI at 3 T, and had a comprehensive neurological
and cognitive assessment. Probability mapping of GM
lesions marked on the DIR scans and voxel- based
morphometry (assessing GM atrophy) were carried out.
The associations of GM lesion load and GM volume with
clinical scores were tested.
Results DIR-visible GM lesions were most commonly
found in the right cerebellum and most apparent in
patients with primary progressive MS. Deep GM
structures appeared largely free from lesions, but showed
considerable atrophy, particularly in the thalamus,
caudate, pallidum and putamen, and this was most
apparent in secondary progressive patients with MS.
Very little co-localisation of GM atrophy and lesions was
seen, and this was generally conﬁned to the cerebellum
and postcentral gyrus. In both regions, GM lesions and
volume independently correlated with physical disability
and cognitive performance.
Conclusions DIR-detectable GM lesions and GM
atrophy do not signiﬁcantly overlap in the brain but,
when they do, they independently contribute to clinical
disability.
INTRODUCTION
Grey matter (GM) pathology has emerged as a sig-
niﬁcant and clinically relevant component of mul-
tiple sclerosis (MS). Advances in MRI technology
have allowed the assessment of GM pathology in
MS in vivo. Both GM volume loss (atrophy) and
GM lesions occur in MS, and both correlate with
neurological and cognitive deﬁcits.1 However, a
key question is whether they share a common
pathogenic mechanism, in particular whether
lesions are the cause of atrophy or are caused by an
independent process that contributes to clinical
outcomes.
Histopathological studies have identiﬁed exten-
sive cortical demyelination in people with MS and
in those with progressive disease, GM lesion
volume may exceed that of WM lesions.2 However,
it has proven difﬁcult to detect in vivo GM lesions
using conventional MRI techniques. Only a small
percentage of GM lesions are identiﬁed on
T2-weighted (<10%) and on ﬂuid-attenuated
inversion recovery (FLAIR) scans.3 The develop-
ment of double inversion recovery (DIR) MRI has
nearly doubled the detection of GM lesions.4 DIR
studies demonstrate that GM lesions are spread
throughout the cortex, appear early in the course
of the disease and accumulate over time.5 6
Deep and cortical GM atrophy is now well-
recognised in MS and appears to accelerate as
patients with MS enter a progressive phase of the
disease.1 GM atrophy is thought to mark irreversible
tissue loss and it is likely to reﬂect a combination of
neuronal morphological changes and loss, and glial
abnormalities.1 Previous in vivo work provides
insight into the mechanisms of GM injury in MS.
Two studies have assessed the relationship between
GM atrophy and WM injury, and these showed that
lesions in connecting WM tracts are associated with
deep GM atrophy.7 8 Lesions could directly cause
localised atrophy, as suggested by pathological
studies showing axonal transection and loss in cor-
tical lesions.1 There has been little histopathological
work examining the co-localisation of cortical
atrophy and demyelination, but in the only study we
are aware of, local cortical thickness did not correl-
ate with demyelination.9 However, ﬁxation can
affect cortical thickness (and ﬁxation time may be
correlated with it9), and so it is possible that this
may have obscured an association. As such, it is pref-
erable to look for associations in fresh tissue samples
or, better still, in vivo.
This study sought to clarify the spatial overlap
between GM atrophy and GM lesions, as well as
their independent relationship with cognitive and
physical disability, in a large cohort of patients with
MS and in different MS subtypes.
METHODS
We recruited 80 people who fulﬁl the following
inclusion criteria: diagnosis of clinically deﬁnite
MS;10 absence of a relapse or use of corticosteroids
within the preceding 4 weeks; age <65 years; and
no other neurological conditions which could have
inﬂuenced the pattern of GM atrophy. Thirty
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healthy volunteers with no known neurological disease were
also studied. Patients were consecutively recruited from the
National Hospital’s specialist MS clinics. Status of disease modi-
fying therapy (DMT), antidepressant for either depression or
neuropathic pain, and benzodiazepine for spasms or insomnia
were recorded. All participants gave written informed consent.
Clinical status was assessed using the Expanded Disability
Status Scale (EDSS)11 and the MS functional composite score
(MSFC) which includes walking speed on the 25-foot Timed
Walk Test (25TWT), 9-hole Peg Test (9HPT) and the Paced
Auditory Serial Addition Test (PASAT). Z-scores of these tests
were calculated using published means and SDs. Levels of
anxiety and depression were also assessed using the Hospital
Anxiety and Depression Scale.12
All subjects underwent cognitive testing to assess executive
function and memory. Executive function was assessed using the
Hayling Sentence Completion Task13 and Stroop Task,14 from
which averaged z-scores were calculated on the basis of healthy
control performance, and the Symbol Digit Modalities Test
(SDMT), from which the age-adjusted z-scores were calculated
based on published normative values.15 Memory function was
evaluated using a composite score of story recall (immediate and
30 min delay) and ﬁgure recall (immediate and 30 min delay)
from the Adult Memory and Information Processing Battery,16
and word and face recognition from the Recognition Memory
Test;17 z-scores based on the performance of the control sample
were also calculated for these tests. When participants were not
able to complete the task, their missing data would not be con-
sidered for the task’s analysis; these were executive function in
one patient with primary progressive MS (PPMS), 25TWT in 3
PPMS, 1 relapsing–remitting MS (RRMS) and 9 patients with
secondary progressive MS (SPMS), and 9HPT in 1 RRMS and
1 patient with SPMS.
MRI protocol
Brain MRI was performed on a Phillips 3 T Achieva TX system
(Philips Healthcare, Best, the Netherlands) using a 32-channel
receive-only coil. T1-weighted (TR=6.9 ms, TE=3.1 ms,
TI=824.5 ms, SENSE=2, voxel size=1×1×1 mm), turbo
FLAIR (TR=8000 ms, TE=125 ms, TI=2400 ms, SENSE=1.3,
voxel size=1×1×3 mm), and DIR (TR=16 000 ms,
TE=9.9 ms, TI=2400/325 ms, SENSE=4.16, 1×1×3 mm)
sequences were acquired.
Image registration and lesion mapping
To limit the impact of WM lesions on tissues segmentations,
T1-weighted (T1w) hypointense lesions were ﬁlled18 and the
lesion-ﬁlled T1w images were then segmented using SPM8
(http://www.ﬁl.ion.ucl.ac.uk/spm/). Anatomical normalisation to
Montreal Neurological Institute (MNI) space was achieved via a
custom diffeomorphic anatomical registration through exponen-
tiated Lie algebra (DARTEL) template,19 generated from all sub-
jects’ (N=110) GM tissue segmentations. To make use of MNI
atlases, the DARTEL GM template was afﬁne-registered to the
MNI standard space, and each subject’s T1-weighted GM was
ﬁrst non-linearly registered to the DARTEL template, and subse-
quently afﬁne registered to MNI using the DARTEL to MNI
transformation, moving it into MNI template space. This pipe-
line reduces the adverse effect of disease-associated brain
atrophy on the registration accuracy. Spatially normalised
T1-weighted images were averaged over subjects to form a
study-speciﬁc T1-weighted MNI-space template. When spatially
normalising the segmented GM images to MNI space (via the
DARTEL and afﬁne transformations), the images were
modulated by the Jacobian determinants so that intensities rep-
resent the amount of deformation needed to normalise the
images. All registrations were reviewed by SvdP to conﬁrm their
accuracy. Modulated, normalised, segmented GM images were
smoothed with an 8 mm full-width at half-maximum Gaussian
kernel.20
GM lesions were marked on the DIR scans using JIM (V.6.0,
Xinapse Systems, Northants, UK) by two independent raters
(VS and SvdP) according to consensus guidelines.21 Marking of
lesions was compared between raters and a consensus was
reached on all lesions. Subsequently, one in ﬁve scans were ana-
lysed by DC, after which a ﬁnal consensus was reached. Total
GM lesion volume was then calculated.
Each participant’s DIR scan was afﬁne registered to their
T1-weighted scan; their DIR-to-T1 afﬁne transformation,
T1-to-DARTEL deformation ﬁeld and DARTEL-to-MNI afﬁne
transformation were combined and used to move the binarised
GM lesion mask into MNI space. All registrations were carried
out in SPM8. After a nearest-neighbor interpolation, an 8 mm
full-width at half-maximum Gaussian Kernel was then used to
smooth the normalised lesion masks.
Two patients (one with SPMS, one with PPMS) were excluded
from the subsequent imaging analysis due to inadequate
registration.
Co-localisation of GM atrophy and lesions
Voxel-based morphometry (VBM) and GM lesion probability
mapping (LPM) analyses were carried out in SPM8. Two types
of analyses were carried out: voxel-wise comparisons and region
of interest (ROI) analyses. For voxel-wise VBM comparison
between groups, we used a signiﬁcance level of 0.05 (family
wise error (FWE) corrected). For voxel-wise LPM, we used a
signiﬁcance level of 0.001 (uncorrected). This threshold was
used as no lesion clustering was found at 0.05 (FWE corrected).
In VBM and LPM comparisons, people with MS were com-
pared to healthy controls to assess areas signiﬁcantly more
affected in people with MS.
To determine co-localisation of volume loss and DIR-visible
GM lesions, permutation tests were run using Randomise22
implemented in FSL (FMRIB’s software library, http://www.
fmrib.ox.ac.uk/fsl). For each of the MS groups, the following
regression model was tested per voxel (ie, with LPM as a voxel-
wise covariate; sometimes known as biological parametric
mapping23):
VBM ¼ LPM B1 þ age B2 þ sex B3
þ total intracranial volume B4 þ intercept
Total intracranial volume (ICV) was estimated by summing
the thresholded GM, white matter (WM) and cerebrospinal
ﬂuid volumes using the ‘get_totals’ function in SPM8.
FSL Randomise uses a non-parametric permutation-testing
procedure that derives an empirical null distribution without
making assumptions about the normality of the data. The tests
were performed in an inclusive GM mask (the average of the
GM segments over subjects, thresholded at 0.5), using a cluster-
forming threshold, and an uncorrected cluster-extent-based sig-
niﬁcance level of 0.01, with 5000 permutations.
The second analysis employed an ROI approach. ROIs
involved in tasks assessing clinical and cognitive functioning in
MS24 25 were chosen a priori. These regions were the bilateral
cerebellum, medial temporal lobe, postcentral gyrus, precentral
gyrus, insula, prefrontal cortex and thalamus (ﬁgure 1). Masks
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for these regions were created by using Freesurfer to automatic-
ally segment the MNI-space cohort-speciﬁc T1-weighted tem-
plate.26 27 For each GM ROI and in each patient, the total GM
lesion volume and the GM volume were extracted from the
VBM and LPM images, and co-localisation between atrophy
and lesion load was assessed using linear regression analyses,
correcting for age, sex, and ICV.
Associations of disability with GM lesion load and GM
atrophy
To explore the associations of DIR-visible GM lesion load and
GM atrophy with clinical measures (EDSS, PASAT, 9HPT,
25TWT, executive function and memory function), voxel-wise
and ROI analyses were carried out. The ﬁrst analysis, based on a
voxel-wise factorial design, was conducted in SPM8, including
age, sex and ICV, and using VBM or LPM values. In all voxel-
wise comparisons, a cluster threshold of ﬁve voxels was applied.
Linear regression models used EDSS, PASAT, 9HPT, 25TWT,
executive function and memory function as the dependent vari-
ables; GM lesion load and GM volume extracted from the ROIs
were used as the independent variables. Age, sex and ICV were
also added to the model as additional covariates. SPSS (V.21.0.
Armonk, New York, USA: IBM Corp) was used to conduct this
analysis. Differences between subtypes in scores, volume loss
and lesion load were analysed using unpaired t tests (for VBM
values) or non-parametric tests (for lesion-loads since they were
non-normally distributed). When both GM lesion load and GM
atrophy within a given ROI were associated with clinical per-
formance, a linear regression model including lesion load, total
GM volume, age and sex was run to determine the independent
contribution of each to the outcome of interest. Shapiro-Wilk
tests were used to assess normality of residuals of the linear
regression analyses and unpaired t tests.
RESULTS
Demographics and clinical performance
Thirty of the MS group had relapsing remitting MS (RRMS),
25 had PPMS, and 25 had SPMS. Demographics are shown in
table 1.
All MS subgroups differed signiﬁcantly in their EDSS scores
(all p<0.05), with SPMS having a higher EDSS than patients
with PPMS, who in turn had a higher EDSS than patients with
RRMS (see table 1). All patient groups had signiﬁcantly higher
levels of depression than controls (all p<0.05), but no signiﬁ-
cant difference was found between subgroups. Anxiety levels
were comparable between patients and controls. People with
MS performed worse than healthy controls in all clinical
domains. Patients had poorer executive functioning and
memory function than healthy controls (all p<0.01). Memory
functioning was best in patients with RRMS, followed by
patients with PPMS, who in turn performed better than the
SPMS subgroup (p<0.05 and p<0.01, respectively). When cor-
recting for depression on clinical functioning, except for the
subgroup comparison of patients with SPMS with PPMS on
memory function, all group comparisons remained signiﬁcant
on all domains.
GM atrophy
People with MS showed signiﬁcant GM atrophy compared to
controls (ﬁgure 2A), predominantly in deep GM structures (thal-
amus, pallidum, putamen and caudate) in addition to a few small
regions in the frontal (0.09 cm3), insular (0.06 cm3) and tem-
poral lobes (0.12 cm3). Similarly, in the a priori deﬁned ROIs (ie,
cerebellum, medial temporal lobe, postcentral gyrus, precentral
gyrus, insula, prefrontal cortex and thalamus, ﬁgure 1), mean
GM volume was signiﬁcantly smaller in patients than controls in
the thalamus (p<0.001) and insula (p<0.05). Subgroup ana-
lyses, which showed that the most extensive atrophy in the deep
GM regions and cortical areas was seen in SPMS, are reported in
the online supplementary material.
GM lesions
In patients, 1476 DIR visible lesions were found throughout the
GM (neocortex: 1276, cerebellum: 154, deep GM: 46), with a
mean total lesion volume of 1.20 cm3 (SD=0.92 cm3). Fourteen
GM lesions were identiﬁed in healthy controls (in 4
participants).
At a threshold of p<0.001, patients had signiﬁcantly higher
GM lesion probability only in the right cerebellar hemisphere
when compared with healthy controls (0.07 cm3, tmax=3.37;
ﬁgure 2B). No deep GM structures showed a signiﬁcantly
increased lesion probability at this threshold or at a lower
threshold (p<0.01, uncorrected). However, at this lower thresh-
old, additional cortical areas showed increased lesion probabil-
ity, notably the right precentral and postcentral gyri, bilateral
supplementary motor area, and bilateral temporal lobes (data
not shown). People with MS had signiﬁcantly more lesions in
every ROI than healthy volunteers (all p<0.001). Subgroup ana-
lyses, which showed that PPMS and SPMS had regions of
higher GM lesion probability than healthy controls, are detailed
in the online supplementary material.
Co-localisation of GM atrophy and lesions
In the whole MS group, voxel-wise analyses showed that there
was little co-localisation of GM atrophy and lesions. Overall the
volume of co-localisation was much smaller (less than 1 cm3)
when compared with total brain GM volumes (>500 cm3).
Areas that showed a signiﬁcant association between a higher
probability of a voxel being lesional and smaller GM volume
were scattered throughout the brain, particularly in the cerebel-
lum (ﬁgure 2C). ROI analyses found that increased GM lesion
load was signiﬁcantly associated with reduced GM volume
Figure 1 A priori deﬁned regions of
interest. A priori deﬁned regions that
were used in the present study:
cerebellum, insula, precentral gyrus,
postcentral gyrus, prefrontal cortex,
medial temporal lobe and thalamus.
Regions are overlaid on the
cohort-speciﬁc MNI-space template
(x=−43, y=3, z=−15).
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within the cerebellum (B=−17.76, p<0.001) and postcentral
gyrus (B=−4.77, p=0.037). The greatest extent of
co-localisation was found in the PPMS cohort, while no
co-localisation was seen in any group in the deep GM regions
(see online supplementary material for more details on the sub-
group analyses).
Associations of GM atrophy and lesion load with clinical
status
Voxel-wise models at p<0.05 (FWE corrected) in people with
MS revealed an association between lower executive function
scores and decreased left putamen volume (0.10 cm3), which
was the only signiﬁcant voxel-wise association of volume loss
with any clinical metric. Furthermore, at p<0.001 (uncor-
rected), increased lesion probability in the cerebellum in particu-
lar was associated with lower performance in executive
function, TWT speed and PASAT (table 2).
ROI analyses showed that cerebellar volume loss and
increased GM lesion volume were associated with poorer func-
tioning in all cognitive domains tested (table 3). In addition,
lesions and volume loss within the postcentral gyrus were asso-
ciated with cognitive performance and physical disability in
almost all domains tested (ie, executive function, memory func-
tion, TWT speed, PASAT, 9HPT). Overall, lower functional
scores were only weakly linked to GM lesion or atrophy
clusters.
DISCUSSION
The present study assessed the distributions of DIR-visible GM
lesions and GM atrophy in patients with MS, aiming to deter-
mine if they co-localise and if they both contribute to clinical
outcomes. Co-localisation was at best modest, with the majority
of atrophy occurring in regions that showed few GM lesions. Of
the GM regions found to be consistently atrophic or to contain
lesions, only the cerebellum and postcentral gyrus showed asso-
ciations between both types of pathology, and physical and cog-
nitive function.
Deep GM volume was reduced in patients compared to con-
trols. This is in line with previous ﬁndings.1 28 More limited
cortical atrophy was also seen in regions consistent with past lit-
erature, including the right lateral prefrontal cortex,29 the left
temporal and prefrontal cortex,30 and the bilateral superior and
medial frontal gyrus and orbitofrontal regions.31 In addition,
small areas of cortical atrophy were seen in the frontal, insular
and temporal lobes, as reported previously.5 32 The most exten-
sive atrophy was seen in SPMS and a feature common to all sub-
types was thalamic atrophy, which was particularly extensive in
the SPMS group; this is in line with previous ﬁndings.28 33
GM lesions were found throughout the cerebral and cerebel-
lar cortex, particularly in the right cerebellum, but rarely in the
deep GM structures. Co-localisation between GM atrophy and
GM lesions was observed only when lower statistical thresholds
were used, and then too mainly in the cortical regions. It was
Table 1 Demographics and clinical performance
PPMS RRMS SPMS All patients Healthy controls
Females/males 14/11 20/10 14/11 48/32 18/12
Age (years)* 52.5 (9.8) 42.5 (9.6) 52.8 (7.6) 48.8 (10.2) 37.8 (11.8)
Disease duration (years)† 12.0 (7.4) 11.5 (10.5) 24.0 (8.2) 15.6 (10.5) –
DMT (number of patients) 1 20 7 28 –
Pychotropic drugs (number of patients) 6 8 9 24 –
Benzodiazepines (number of patients) 3 0 0 3 –
Median EDSS (range)‡ 6.0 (0.0–6.5) 1.75 (1.0–6.5) 6.5 (4.5–8.5) 5.75 (0.0–8.5) –
HADS depression§ 6.40 (3.59) 5.83 (3.56) 7.12 (3.69) 6.41 (0.40) 2.87 (3.50)
HADS anxiety 6.08 (4.33) 6.93 (3.31) 7.16 (4.18) 6.74 (0.44) 5.77 (4.41)
z PASAT −0.70 (1.38) −0.69 (1.32) −0.94 (1.12) −0.77 (1.27) 0.12 (1.05)
z 9HPT −1.00 (1.13) −0.66 (0.65) −1.16 (0.90) −0.93 (0.92) 0.63 (0.61)
z 25TWT 0.32 (0.97) 0.00 (1.03) 0.56 (1.01) 0.24 (1.02) −0.44 (0.08)
Composite z MSFC −0.62 (0.81) −0.41 (0.76) −0.77 (0.66) −0.56 (0.76) –
Hayling 4.80 (2.02) 5.17 (2.09) 4.64 (2.43) 4.89 (2.16) 6.17 (1.76)
Stroop 174.4 (76.7) 135.83 (36.9) 174.58 (80.9) 158.59 (66.7) 109.80 (20.0)
SDMT 43.44 (11.91) 52.33 (9.88) 41.09 (10.45) 46.23 (11.71 63.10 (9.91)
Composite z executive¶ −1.58 (1.69) −0.71 (1.09) −1.51 (1.55) −1.23 (1.48) 0.23 (0.69)
Story recall immediate 30.04 (10.96) 33.97 (11.35) 27.76 (11.44) 30.80 (11.42) 37.13 (10.35)
Story recall delay 27.20 (12.29) 31.57 (10.93) 24.80 (12.22) 28.09 (11.97) 34.90 (10.31)
Figure recall immediate 51.09 (15.41) 62.20 (11.14) 51.57 (16.17) 55.80 (14.86) 67.67 (11.94)
Figure recall delay 48.73 (15.84) 60.07 (11.22) 48.67 (14.83) 53.37 (14.72) 66.30 (12.06)
RMT Words 46.17 (3.63) 47.60 (2.43) 45.61 (3.69) 46.56 (3.31) 49.00 (1.26)
RMT Faces 40.21 (5.27) 42.33 (4.23) 37.43 (5.53) 40.21 (5.31) 44.27 (3.20)
Composite z memory** −1.30 (1.15) −0.55 (0.89) −1.63 (1.27) −1.13 (1.18) 0.00 (0.58)
Mean values are presented and values in parentheses are SDs, unless specified otherwise. Clinical scores presented in bold are used in image analyses to study different domains of
clinical function.
*Patients with RRMS were significantly younger than patients with PPMS and SPMS (both p<0.001).
†Patients with SPMS had longer disease duration than patients with RRMS and SPMS (both p<0.001).
‡All MS subgroups differed significantly (all p<0.05).
§All MS subgroups differed in their levels of depression from controls (all p<0.05), but not between each other.
¶Patients performed worse than healthy controls (p<0.01).
**Controls performed than patients (p<0.01). Patients with RRMS performance was better than patients with PPMS, who in turn performed better than the SPMS subgroup (p<0.05
and p<0.01, respectively).
9HPT, 9-hole Peg Test; MS, multiple sclerosis; PASAT, Paced Auditory Serial Addition Test; PPMS, progressive primary multiple sclerosis; RRMS, relapsing–remitting multiple sclerosis;
SDMT, Symbol Digit Modalities Test; SPMS, secondary progressive multiple sclerosis; 25TWT, 25-foot Timed Walk Test.
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rarely seen in the deep structures, which showed atrophy. Work
by Wegner et al9 has shown pathological changes within cortical
lesions and to a lesser degree, in non-lesional cortex, but did
not ﬁnd an association between demyelination and cortical
thickness, suggesting that demyelination per se is not directly
responsible for cortical atrophy. Our ﬁndings are in agreement
with this and we, therefore, suggest with caveats (see the discus-
sion of the limitations of this work below) that GM atrophy and
DIR-visible GM lesion are often not directly linked. This view is
supported by recent ﬁndings that cortical MTR abnormalities,
which is heavily inﬂuenced by demyelination, rarely co-localises
with atrophy in MS,20 further suggesting differences in patho-
genic mechanisms.
Previous papers have demonstrated that the topographic dis-
tribution of GM lesions is rather similar between patient sub-
types, and that PPMS and RRMS share more similarities than
differences in terms of GM lesion number, volume and topo-
graphic distribution.5 Additionally, there are differences in GM
atrophy between subtypes of MS which involve not only a
selective involvement of brain regions but also an increased
extent of atrophy in common regions, such as the thalamus, in
the progressive phase of MS.34 We conﬁrmed these ﬁndings in
this paper and therefore, combined all the phenotypes to investi-
gate the overlap between lesions and atrophy. Based on our
observed differences between the subgroups, we performed a
sample size calculation to estimate the number of subjects a
future study might require to detect (with 80% power at 5%
signiﬁcance) a difference between subgroups in the volume of
the prefrontal cortex (which was the ROI with the least power
to detect differences) of 8 cm3 (as observed in our study), as
well as in the proportion of lesional voxels of 0.22, using the
means and SDs of concentrations provided by our data and
standard methods for comparisons of means.35 We found that
the sample size required to detect signiﬁcant GM volume differ-
ences between subtypes of MS was 75 per group for GM
volume and 39 per group for GM lesion probability. This
Figure 2 Grey matter (GM)
pathology in MS. The progressive
primary multiple sclerosis (PPMS)
group is presented in green, relapsing–
remitting multiple sclerosis (RRMS) in
blue and secondary progressive
multiple sclerosis (SPMS) in orange on
the cohort-speciﬁc MNI-space
template. (A) All multiple sclerosis
(MS) subtypes show pronounced deep
volume loss compared to controls at
p<0.05 (family wise error, FWE
corrected). In particular, patients with
relapse onset have severe deep
atrophy. Coordinates of sections are x=
−14, y=−22, z=3. (B) Areas showing
clusters of increased GM lesion
probability in patients compared to
controls at p<0.001, uncorrected. The
RRMS group did not show clusters of
increased GM lesion probability at this
threshold, while SPMS showed
increased cerebellar lesion load and
PPMS had clusters of increased lesion
probability throughout the cerebral and
especially the cerebellar cortex.
Coordinates of sections are x=−5,
y=−13, z=−39. (C) Areas showing a
signiﬁcant correlation of atrophy and
increased probability of a GM voxel
being lesional (at p<0.01, uncorrected)
in all patient groups together.
Coordinates of sections are x=29,
y=−66, z=−28.
Table 2 Regions with increased lesion probability associated with
poorer performance in clinical domains (thresholded at p<0.001
uncorrected)
Domain Region Side cm3
Peak T
value
MNI coordinates
of local maxima
Executive
function
Precentral gyrus R 0.08 3.75 48 8 29
Inferior frontal
operculum
R 0.24 3.84 49 9 28
Anterior cingulum L 0.07 3.48 −2 43 14
Cerebellum crus1 R 0.18 3.51 40 −65 −37
Cerebellum crus2 R 0.04 3.48 40 −65 −38
Cerebellum 8 R 0.01 3.32 38 −57 −47
Memory
function
Superior frontal
lobe
R 0.01 3.29 17 3 72
25TWT Cerebellum crus2 L 0.02 3.31 −30 −77 −36
zPASAT Supramarginal
gyrus
R 0.01 3.28 58 −39 33
Cerebellum crus1 L 0.01 3.34 −29 −60 −38
Cerebellum 6 L 0.03 3.59 −27 −58 −35
z9HPT Precentral gyrus R 0.04 3.36 11 −24 75
Lesion load in the cerebellum in particular is related to poorer executive, TWT speed,
and PASAT performance.
9HPT, 9-hole Peg Test; zPASAT, Paced Auditory Serial Addition Test; 25TWT, 25-foot
Timed Walk Test.
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sample size calculation can be used by future studies that will
aim to investigate the differences between groups in lesion prob-
ability and GM volume.
With regard to the association between GM lesions and atrophy
with clinical disability, one interesting observation from the ROI
analysis was that both GM lesion volume and atrophy in the post-
central gyrus (the primary somatosensory cortex) were linked to
clinical measures of physical disability and to worse performance
in almost all cognitive domains. Additionally, a signiﬁcant and
independent association was found between cerebellar lesion load
and atrophy with lower physical and cognitive performance. This
ﬁts with the known involvement of the cerebellum in sensorimotor
and cognitive function.36 In addition, the postcentral gyrus and
cerebellum, which are both functionally and structurally con-
nected,36 were the only regions in which lesion burden and
volume loss were linked. Further work focusing on these two
regions may shed light on the mechanisms of disability in MS.
Using the voxel-wise analysis, we found that deep GM atrophy
was generally not linked to functional outcomes, except for an
association between executive function and a small region of
atrophy in the putamen. This suggests that other processes, includ-
ing white matter damage and brain network dysfunction, may be
involved in cognitive dysfunction.37 38
A number of limitations of this work should be taken into
consideration. For LPM, some forms of cortical lesions may be
easier to detect on DIR scans than others. DIR scans detect
about a ﬁfth of cortical lesions (18%) and less than a tenth of
deep GM lesions (7%); also, while subpial lesions are the most
abundant type seen in postmortem studies, these are rarely
observed using DIR.4 Recent pathological work showed deep
GM lesions and neurodegeneration in the deep GM that, in
combination with cortical and white matter lesions, contributed
to the clinical deﬁcits;39 this insensitivity for DIR to detect deep
GM lesions may partly explain the limited overlap found
between lesions and atrophy in deeper GM structures.
However, since the DIR-visible GM lesions represent the ‘peak’
of the real GM lesions, patients with higher DIR-visible lesions
will also have higher number of real GM lesions; in this study
we have investigated if these patients also have a greater amount
of atrophy. Phase Sensitive Inversion Recovery MRI detects two
to three times more GM lesions and so may increase the overall
sensitivity of LPM analyses, but this sequence may still be less
sensitive to subpial lesions than the other GM lesion subtypes.40
However, recent work has shown similar dissociations between
the localisation of atrophy and demyelination, as measured by
MTR,20 indicating that separations in the localisation and
drivers of pathology are likely. A second limitation is that due to
the low-frequency of overlapping lesions between patients we
used a signiﬁcance level of 0.001 (uncorrected) for the LPM
analysis. While lowering the threshold increases the chance of a
type I error, only one per 1000 voxels would show a false posi-
tive. In addition, the applied cluster threshold further reduces
the number of false positive ﬁndings. Few studies have examined
the effect of psychotropic drugs on cognition in MS. Oken
et al41 found no signiﬁcant effect of SSRIs and benzodiazepines
on the PASAT, stroop, verbal memory or executive function test
performance. These did, however, show an effect on a reaction
time test. While use of psychotropic drugs may have subtly
inﬂuenced our ﬁndings, the concomitant alleviation of depres-
sion, which is itself linked to cognitive impairment, is likely to
have balanced out these effects. Not all patients were able to
ﬁnish all clinical tasks due to disability, which led to the exclu-
sion of their missing data from this task’s analysis. It is, there-
fore, likely that the effects found were an underestimation of
the real effects of MS as the excluded disabled patients were
likely to also have the poorest cognitive function.
The present study assessed the distributions of DIR-visible
GM lesions and GM atrophy in patients with different subtypes
of MS and their relationship with clinical outcomes. We found
that GM lesions (as seen using DIR) and GM atrophy do not
usually co-localise, indicating that they are not directly spatially
coupled. We also found that both GM lesions and atrophy sep-
arately contributed to disability, suggesting that the substrates of
disability in MS are both pathologically and spatially
heterogeneous.
Author afﬁliations
1NMR Research Unit, Queen Square Multiple Sclerosis Centre, UCL Institute of
Neurology, London, UK
2School of Psychology and Cardiff University Brain Research Imaging Centre, Cardiff
University, Cardiff, Glamorgan, UK
3Wellcome Trust Centre for Neuroimaging, UCL Institute of Neurology, London, UK
4Nufﬁeld Department of Clinical Neurosciences, FMRIB Centre, University of Oxford,
Oxford, UK
5Department Anatomy & Neurosciences, Section of Clinical Neuroscience, VU
University Medical Centre, Amsterdam, The Netherlands
6Sara Koe PSP Research Centre, UCL Institute of Neurology, London, UK
7NIHR UCL/UCLH Biomedical Research Centre, London, UK
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EDSS Cerebellum −0.053 0.022 0.018 0.203 2.562 0.960 0.009 0.216
Postcentral gyrus −0.294 0.093 0.002 0.242 5.441 2.326 0.022 0.199
Executive function Cerebellum 0.042 0.015 0.006 0.067 −1.567 0.665 0.021 0.038
Memory function Cerebellum 0.026 0.011 0.020 0.066 −1.205 0.483 0.015 0.072
Postcentral gyrus −2.695 1.164 0.023 0.062
z25TWT Cerebellum 0.014 0.006 0.020 0.156 −0.543 0.244 0.029 0.148
Postcentral gyrus 0.062 0.024 0.014 0.164 −1.574 0.574 0.008 0.176
zPASAT Cerebellum 0.047 0.012 <0.001 0.150
Insula 0.336 0.099 0.001 0.122
Medial temporal lobe 0.286 0.094 0.003 0.098
Postcentral gyrus −2.842 1.399 0.032 0.076
Prefrontal lobe 0.026 0.011 0.025 0.052
z9HPT Cerebellum 0.023 0.009 0.016 0.100
If both volume loss and increased lesion burden is associated, the strongest contributor is presented in bold.
EDSS, Expanded Disability Status Scale; GM, grey matter; z9HPT, 9-hole Peg Test; 25TWT, 25-foot Timed Walk Test; zPASAT, Paced Auditory Serial Addition Test, ROI, region of interest.
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